Nephros (NEPH) Expected to Announce Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is anticipated to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of $0.01 per share and revenue of $5.0180 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.01 EPS for the quarter, meeting the consensus estimate of $0.01. Nephros had a net margin of 6.35% and a return on equity of 12.22%. The business had revenue of $4.73 million during the quarter, compared to analyst estimates of $4.45 million.

Nephros Stock Performance

Shares of NEPH opened at $3.07 on Tuesday. The company has a 50 day moving average price of $3.27 and a 200-day moving average price of $4.28. Nephros has a fifty-two week low of $1.78 and a fifty-two week high of $6.42. The stock has a market capitalization of $32.66 million, a PE ratio of 27.91 and a beta of 1.47.

Institutional Trading of Nephros

Institutional investors have recently modified their holdings of the company. Topline Capital Management LLC grew its position in shares of Nephros by 13.1% in the 2nd quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after buying an additional 55,360 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in Nephros in the fourth quarter valued at approximately $112,000. Marshall Wace LLP acquired a new stake in Nephros in the fourth quarter valued at approximately $107,000. Renaissance Technologies LLC grew its holdings in Nephros by 25.8% in the fourth quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock worth $506,000 after purchasing an additional 21,272 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its position in shares of Nephros by 57.1% during the fourth quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock worth $190,000 after purchasing an additional 14,162 shares in the last quarter. 41.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “hold (c)” rating on shares of Nephros in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Nephros has an average rating of “Moderate Buy” and a consensus target price of $6.00.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.